FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200165712> ?p ?o ?g. }

• W4200165712 endingPage "7538" @default.
• W4200165712 startingPage "7538" @default.
• W4200165712 abstract "Irbesartan (IR) is an angiotensin II receptor antagonist drug with antihypertensive activity. IR bioavailability is limited due to poor solubility and first-pass metabolism. The current investigation aimed to design, develop, and characterize the cyclodextrin(s) (CD) complexed IR (IR-CD) loaded solid lipid nanoparticles (IR-CD-SLNs) for enhanced solubility, sustained release behavior, and subsequently improved bioavailability through oral administration. Based on phase solubility studies, solid complexes were prepared by the coacervation followed by lyophilization method and characterized for drug content, inclusion efficiency, solubility, and in vitro dissolution. IR-CD inclusion complexes demonstrated enhancement of solubility and dissolution rate of IR. However, the dissolution efficiency was significantly increased with hydroxypropyl-βCD (HP-βCD) inclusion complex than beta-CD (βCD). SLNs were obtained by hot homogenization coupled with the ultrasonication method with IR/HP-βCD inclusion complex loaded into Dynasan 112 and glycerol monostearate (GMS). SLNs were evaluated for physicochemical characteristics, in vitro release, differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), and physical stability at room temperature for two months. The optimized SLNs formulation showed particle size, polydispersity index, zeta potential, assay, and entrapment efficiency of 257.6 ± 5.1 nm, 0.21 ± 0.03, -30.5 ± 4.1 mV, 99.8 ± 2.5, and 93.7 ± 2.5%, respectively. IR-CD-SLN and IR-SLN dispersions showed sustained release of IR compared to the IR-CD inclusion complexes. DSC results complimented PXRD results by the absence of IR endothermic peak. Optimized IR-CD complex, IR-SLN, and IR-CD-SLN formulations were stable for two months at room temperature. Thus, the current IR oral formulation may exhibit improved oral bioavailability and prolonged antihypertensive activity, which may improve therapeutic outcomes in the treatment of hypertension and heart failure." @default.
• W4200165712 created "2021-12-31" @default.
• W4200165712 creator A5000041390 @default.
• W4200165712 creator A5001166407 @default.
• W4200165712 creator A5058346561 @default.
• W4200165712 creator A5068229132 @default.
• W4200165712 date "2021-12-13" @default.
• W4200165712 modified "2023-10-13" @default.
• W4200165712 title "Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization" @default.
• W4200165712 cites W1579046626 @default.
• W4200165712 cites W1973943566 @default.
• W4200165712 cites W1995008519 @default.
• W4200165712 cites W1996852269 @default.
• W4200165712 cites W1999166183 @default.
• W4200165712 cites W2010016292 @default.
• W4200165712 cites W2011920500 @default.
• W4200165712 cites W2013871444 @default.
• W4200165712 cites W2022258204 @default.
• W4200165712 cites W2046017608 @default.
• W4200165712 cites W2046845840 @default.
• W4200165712 cites W2048287878 @default.
• W4200165712 cites W2052344045 @default.
• W4200165712 cites W2054139139 @default.
• W4200165712 cites W2057632167 @default.
• W4200165712 cites W2059195099 @default.
• W4200165712 cites W2062465466 @default.
• W4200165712 cites W2066362724 @default.
• W4200165712 cites W2069572791 @default.
• W4200165712 cites W2069972483 @default.
• W4200165712 cites W2073394985 @default.
• W4200165712 cites W2074582913 @default.
• W4200165712 cites W2080292900 @default.
• W4200165712 cites W2080370993 @default.
• W4200165712 cites W2093357069 @default.
• W4200165712 cites W2095033482 @default.
• W4200165712 cites W2131860317 @default.
• W4200165712 cites W2161868603 @default.
• W4200165712 cites W2169946060 @default.
• W4200165712 cites W2326495514 @default.
• W4200165712 cites W2414781026 @default.
• W4200165712 cites W2546906904 @default.
• W4200165712 cites W2567320176 @default.
• W4200165712 cites W2573896644 @default.
• W4200165712 cites W2593919943 @default.
• W4200165712 cites W2594335672 @default.
• W4200165712 cites W2600333833 @default.
• W4200165712 cites W2606666788 @default.
• W4200165712 cites W2790041371 @default.
• W4200165712 cites W2800136256 @default.
• W4200165712 cites W2802983224 @default.
• W4200165712 cites W2901569630 @default.
• W4200165712 cites W2971645342 @default.
• W4200165712 cites W3010288120 @default.
• W4200165712 cites W3025422232 @default.
• W4200165712 cites W3035986373 @default.
• W4200165712 cites W3045368094 @default.
• W4200165712 cites W3049064379 @default.
• W4200165712 cites W3060005008 @default.
• W4200165712 cites W3072431444 @default.
• W4200165712 cites W3086610332 @default.
• W4200165712 cites W3131769770 @default.
• W4200165712 cites W3133861417 @default.
• W4200165712 cites W3143735692 @default.
• W4200165712 cites W65005365 @default.
• W4200165712 doi "https://doi.org/10.3390/molecules26247538" @default.
• W4200165712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34946619" @default.
• W4200165712 hasPublicationYear "2021" @default.
• W4200165712 type Work @default.
• W4200165712 citedByCount "9" @default.
• W4200165712 countsByYear W42001657122022 @default.
• W4200165712 countsByYear W42001657122023 @default.
• W4200165712 crossrefType "journal-article" @default.
• W4200165712 hasAuthorship W4200165712A5000041390 @default.
• W4200165712 hasAuthorship W4200165712A5001166407 @default.
• W4200165712 hasAuthorship W4200165712A5058346561 @default.
• W4200165712 hasAuthorship W4200165712A5068229132 @default.
• W4200165712 hasBestOaLocation W42001657121 @default.
• W4200165712 hasConcept C11432220 @default.
• W4200165712 hasConcept C121332964 @default.
• W4200165712 hasConcept C13965031 @default.
• W4200165712 hasConcept C147789679 @default.
• W4200165712 hasConcept C155574463 @default.
• W4200165712 hasConcept C155672457 @default.
• W4200165712 hasConcept C171250308 @default.
• W4200165712 hasConcept C178790620 @default.
• W4200165712 hasConcept C181389837 @default.
• W4200165712 hasConcept C185592680 @default.
• W4200165712 hasConcept C187530423 @default.
• W4200165712 hasConcept C192562407 @default.
• W4200165712 hasConcept C199529486 @default.
• W4200165712 hasConcept C39519442 @default.
• W4200165712 hasConcept C43617362 @default.
• W4200165712 hasConcept C71924100 @default.
• W4200165712 hasConcept C86181022 @default.
• W4200165712 hasConcept C88380143 @default.
• W4200165712 hasConcept C97355855 @default.
• W4200165712 hasConcept C98274493 @default.
• W4200165712 hasConceptScore W4200165712C11432220 @default.

• next